View Mobile Site

They only want a fair profit

Until recently, many pregnant women at risk of delivering prematurely could be aided by an obstetrician-recommended workup of a chemical compound, at a cost of about $10 to $20 a dose.
However, the Food and Drug Administration recently approved a specific commercial version, K-V Pharmaceutical’s Makena, which K-V began pricing at $1,500 a dose (citing its need to recoup “research” costs).
K-V also began threatening dispensers of the workup compound, since FDA had anointed Makena with “market exclusivity.”
Update: FDA changed its mind in March and announced that providers of the workup compound could continue to offer it ...


** Subscribers Log in to read this full article.

In order to view premium content, you must purchase a subscription.

Thank you for showing so much interest in our site! Our policies allow 10 free article views each month. To access additional articles including the E-Tribune, please subscribe. Already a print or online subscriber? Just log on to access additional content.

A subscription is required before viewing this article and other premium content.

Already a registered member and have a subscription?

If you have already purchased a subscription, please log in to view the full article.

Are you registered, but do not have a subscription?

If you are a registed user and would like to purchase a subscription, log in to view a list of available subscriptions.

Interested in becoming a registered member and purchasing a subscription?

Join our community today by registering for a FREE account. Once you have registered for a FREE account, click SUBSCRIBE NOW to purchase access to premium content.

Membership Benefits

  • Instant access to creating Blogs, Photo Albums, and Event listings.
  • Email alerts with the latest news.
  • Access to commenting on articles.

Please wait ...